Author’s response to reviews

Title: Safety and efficacy analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation

Authors:

Michaela Doering (Michaela.Doering@med.uni-tuebingen.de)
Carsten Mueller (c.mueller@uni-koeln.de)
Pascal-David Johann (pascal.johann@med.uni-heidelberg.de)
Annika Erbacher (Annika.Erbacher@med.uni-tuebingen.de)
Astrid Kimmig (Astrid.Kimmig@med.uni-tuebingen.de)
Carl-Philipp Schwarze (Carl-Philipp.Schwarze@med.uni-tuebingen.de)
Peter Lang (Peter.Lang@med.uni-tuebingen.de)
Rupert Handgretinger (Rupert.Handgretinger@med.uni-tuebingen.de)
Ingo Mueller (i.mueller@uke.de)

Version: 2 Date: 26 January 2012

Author’s response to reviews: see over
Re: Manuscript submission

Dear Madam,

Thank you for your information. We have clarified the source of data and the ethical regulations for this retrospective analysis. We apologize for these oversights.

Please consider our attached manuscript, “Safety and efficacy analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation” for publication in *BMC Infectious Disease*. Pediatric patients undergoing hematopoietic stem cell transplantation experience prolonged neutropenia, which predisposes for invasive fungal infection. Our retrospective study analyzes the use of posaconazole as oral antifungal monoprophylaxis in 60 pediatric patients, which is the largest cohort of pediatric patients receiving posaconazole as antifungal prophylaxis published to date. We conclude that posaconazole is an effective, safe and well tolerated antimycotic prophylaxis in these pediatric patients. We believe that the readership of *BMC Infectious Disease* will be highly interested in this clinically very relevant work. We would be happy to provide any additional information you may require.

Sincerely,

Dr. Michaela Döring